title: The potential of carcinoembryonic antigen, p53, Ki-67 and glutathion Stransferase-π as clinico-histopathological markers for colorectal cancer.
abstract: OBJECTIVE
  Colorectal cancer is one of the major contributors to cancer death worldwide. Lack of reliable colorectal cancer markers has hampered the management of these cancer patients. Our main purpose was to study the correlation between histopathological variables of colorectal adenocarcinomas and identify histopathological markers that are of prognostic value in patients with colorectal cancer.
  
  
  METHODS
  In the present study, we examined the expression of carcinoembryonic antigen (CEA), p53, Ki-67 and glutathion Stransferase (GST) -π by using immunohistochemical staining methods in 126 colorectal carcinoma patients and evaluated the lymph node metastasis status in these patients by histopathological examination.
  
  
  RESULTS
  The positive rates of CEA, p53, Ki-67 and GST-π expression in the colorectal cancer tissue specimens examined were 95.23%, 55.56%, 53.38% and 82.30%, respectively. Expression of p53 and Ki-67 was significantly correlated with the Dukes stages of the tumor, with higher levels of these proteins in Dukes'C and D tumors than those in Dukes' A and B tumors. Furthermore, the expression of p53, GST-π and Ki-67 correlated with prognosis of patients with colorectal cancer. Additionally, the expression of p53 in colorectal cancer was closely related to the expression of Ki-67 and the expression of GST-π was directly correlated with that of p53.
  
  
  CONCLUSIONS
  The expression of CEA, p53, Ki-67 and GST-π was correlated with various clinical features of patients with colorectal cancer. The combined use of these histopathological markers appeared to be a promising tool in predicting the prognosis of patients with this type of cancer.
authors.affiliation: Departments of General Surgery and ; The First Clinic College , Nanjing Medical University, Nanjing, Jiangsu, 210029, China.
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: He
authors.forename: Chuanbing
authors.initials: C
authors.lastname: Shi
authors.forename: Hao
authors.initials: H
authors.lastname: Wen
authors.forename: Fanglong
authors.initials: F
authors.lastname: Li
authors.forename: Baolin
authors.initials: B
authors.lastname: Wang
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
keywords: Ki-67; carcinoembryonic antigen; colorectal cancer; glutathion stransferase-π; lymph node metastasis; p53
references.citation: Expert Rev Mol Diagn. 2008 May;8(3):277-88
references.pmid: 18598107
references.citation: J Clin Oncol. 1994 Oct;12(10):2043-50
references.pmid: 7931472
references.citation: World J Gastroenterol. 2005 Jun 7;11(21):3245-9
references.pmid: 15929175
references.citation: Nat Clin Pract Oncol. 2004 Dec;1(2):104-11
references.pmid: 16264828
references.citation: Anticancer Res. 2008 Jan-Feb;28(1B):451-7
references.pmid: 18383884
references.citation: Dis Colon Rectum. 2000 Jul;43(7):971-5
references.pmid: 10910245
references.citation: J Pathol. 1996 Dec;180(4):364-70
references.pmid: 9014855
references.citation: Dis Colon Rectum. 1995 Nov;38(11):1176-81
references.pmid: 7587760
references.citation: Cancer. 2000 Apr 15;88(8):1814-9
references.pmid: 10760757
references.citation: Cancer Biol Ther. 2010 Feb;9(4):295-302
references.pmid: 20026903
references.citation: Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):175-82
references.pmid: 10981868
references.citation: Cancer Res. 1995 Jun 15;55(12):2696-702
references.pmid: 7780987
references.citation: Ann Surg Oncol. 2010 Apr;17(4):967-72
references.pmid: 20033322
references.citation: J Clin Oncol. 2003 Jan 15;21(2):241-50
references.pmid: 12525515
references.citation: Cancer Lett. 2004 Apr 15;207(1):109-15
references.pmid: 15050740
references.citation: Anticancer Res. 2009 Oct;29(10):4151-6
references.pmid: 19846965
references.citation: Cancer Res. 1987 Dec 15;47(24 Pt 1):6806-9
references.pmid: 3499981
references.citation: Oncology (Williston Park). 2006 May;20(6):579-87; discussion 588, 594, 596 passim
references.pmid: 16773844
references.citation: J Natl Cancer Inst. 2002 Jun 19;94(12):936-42
references.pmid: 12072547
references.citation: J Clin Oncol. 2004 May 1;22(9):1572-82
references.pmid: 15117979
references.citation: Lancet Oncol. 2009 Nov;10(11):1128
references.pmid: 19880067
references.citation: Jpn J Cancer Res. 1986 Mar;77(3):226-9
references.pmid: 3084412
references.citation: Br J Cancer. 2009 Oct 20;101(8):1282-9
references.pmid: 19773751
references.citation: Br J Cancer. 2005 May 9;92(9):1813
references.pmid: 15856032
references.citation: Anticancer Res. 2009 Nov;29(11):4807-11
references.pmid: 20032439